HemoSonics’ Quantra Wins 2025 Life Sciences Award

HemoSonics LLC has won the Triangle Business Journal 2025 Life Sciences Award in the Best Medical Device Company category for its Quantra Hemostasis System’s work in viscoelastic testing. HemoSonics’ Quantra Hemostasis System accelerates OR decision-making, improves patient outcomes, and reduces healthcare costs by providing optimized coagulation information.

According to North Carolina Biotechnology Center data, North Carolina is home to 840 life sciences companies, with the lion’s share based in the state’s Triangle region. The Triangle Business Journal’s Life Sciences Awards recognize 12 individuals and research organizations from North Carolina’s Research Triangle (Raleigh, Durham, Chapel Hill) that are leading and breaking ground in this field. The life sciences arena’s broad spectrum encompasses biotechnology, pharmaceuticals, clinical research, human health, medical devices and diagnostics, and other related fields.

The HemoSonics Quantra Hemostasis System consists of the Quantra Hemostasis Analyzer, as well as QPlus and QStat Cartridges. The System provides fast, comprehensive whole-blood coagulation analysis at the point of care or in laboratory settings in under 15 minutes, empowering clinicians with information to inform patient-centered decisions that improve care and optimize blood product usage. The Quantra System uses innovative SEER Sonorheometry (Sonic Estimation of Elasticity via Resonance), a proprietary medical-grade ultrasound technology that measures a whole blood sample’s coagulation properties.

HemoSonics’ Quantra System is U.S. Food and Drug Administration-cleared for cardiovascular surgery, trauma, liver transplantation, and major orthopedic surgery. It requires minimal resources to maintain, is easy to operate and interpret, and enables hospitals to standardize a clinically and operationally efficient viscoelastic testing program.

“The Research Triangle Park has long been recognized as a catalyst for technologies in biotechnology, medical devices, and health technology, and this community is one of the key reasons we chose Durham for our headquarters,” HemoSonics President/CEO Bob Roda said. “Innovation is at the heart of what we do at HemoSonics, and we’re thrilled to be mentioned alongside companies who are changing the world for the better through medical and scientific advances.”

HemoSonics’ Quantra Hemostasis System technology has received numerous accolades, including the 2024 TIME Best Inventions, 2024 Fast Company Most Innovative Companies (Medtech), 2024 Edison Awards (Point-of-Care and Therapeutic Solutions), and the 2024 Deloitte Fast 500, which recognizes the fastest-growing companies in North America.

HemoSonics LLC is focused on acute bleeding management, resulting in better patient care and lower overall medical costs. The Quantra Hemostasis Analyzer, HemoSonics’ flagship product, is designed to improve patient outcomes and reduce healthcare costs by providing optimized coagulation information. Based in Durham, N.C., HemoSonics is part of the Stago Group, an in-vitro diagnostics company developing solutions for thrombosis and hemostasis.